- Home
- APLM vs TRIB Comparison
APLM vs TRIB Comparison
Compare APLM & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- TRIB
- Stock Information
- Founded
- APLM 2016
- TRIB 1992
- Country
- APLM United States
- TRIB Ireland
- Employees
- APLM N/A
- TRIB N/A
- Industry
- APLM Blank Checks
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- APLM Finance
- TRIB Health Care
- Exchange
- APLM Nasdaq
- TRIB Nasdaq
- Market Cap
- APLM 15.6M
- TRIB 15.8M
- IPO Year
- APLM N/A
- TRIB N/A
- Fundamental
- Price
- APLM $0.10
- TRIB $1.48
- Analyst Decision
- APLM Strong Buy
- TRIB
- Analyst Count
- APLM 2
- TRIB 0
- Target Price
- APLM $4.25
- TRIB N/A
- AVG Volume (30 Days)
- APLM 1.2M
- TRIB 166.9K
- Earning Date
- APLM 08-14-2024
- TRIB 11-15-2024
- Dividend Yield
- APLM N/A
- TRIB N/A
- EPS Growth
- APLM N/A
- TRIB N/A
- EPS
- APLM N/A
- TRIB N/A
- Revenue
- APLM $2,101,000.00
- TRIB $58,652,000.00
- Revenue This Year
- APLM N/A
- TRIB $17.64
- Revenue Next Year
- APLM N/A
- TRIB $9.84
- P/E Ratio
- APLM N/A
- TRIB N/A
- Revenue Growth
- APLM 70.54
- TRIB 8.60
- 52 Week Low
- APLM $0.10
- TRIB $1.05
- 52 Week High
- APLM $1.79
- TRIB $3.55
- Technical
- Relative Strength Index (RSI)
- APLM 34.54
- TRIB 42.63
- Support Level
- APLM $0.11
- TRIB $1.49
- Resistance Level
- APLM $0.13
- TRIB $1.70
- Average True Range (ATR)
- APLM 0.01
- TRIB 0.16
- MACD
- APLM -0.00
- TRIB -0.03
- Stochastic Oscillator
- APLM 4.02
- TRIB 5.56
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.